2022
Assessment of Hypothetical Out-of-Pocket Costs of Guideline-Recommended Medications for the Treatment of Older Adults With Multiple Chronic Conditions, 2009 and 2019
Zhou T, Liu P, Dhruva SS, Shah ND, Ramachandran R, Berg KM, Ross JS. Assessment of Hypothetical Out-of-Pocket Costs of Guideline-Recommended Medications for the Treatment of Older Adults With Multiple Chronic Conditions, 2009 and 2019. JAMA Internal Medicine 2022, 182: 185-195. PMID: 34982097, PMCID: PMC8728660, DOI: 10.1001/jamainternmed.2021.7457.Peer-Reviewed Original ResearchMeSH KeywordsAgedAtrial FibrillationChronic DiseaseCross-Sectional StudiesDiabetes Mellitus, Type 2Drug CostsHealth ExpendituresHeart FailureHumansHypercholesterolemiaHypertensionMedicare Part CMedicare Part DMultiple Chronic ConditionsOsteoarthritisOsteoporosisPrescription DrugsPulmonary Disease, Chronic ObstructiveRetrospective StudiesUnited StatesConceptsCommon chronic diseasesGuideline-recommended medicationsGuideline-recommended managementPrescription drug plansCross-sectional studyChronic conditionsChronic diseasesPocket costsOlder adultsOutpatient medicationsMedicare prescription drug plansInitial treatmentMedicare Advantage plansRetrospective cross-sectional studyMultiple chronic conditionsMedicare Part D plansPart D plansSubstantial financial burdenAtrial fibrillationMAIN OUTCOMEExclusion criteriaMedicare beneficiariesAnnual outHypothetical patientsMedications
2021
U.S. Prescribing of On-and-Off-Label Medications for Alcohol Use Disorder in Outpatient Visits: NAMCS 2014 to 2016
Wallach JD, Rhee TG, Edelman EJ, Shah ND, O’Malley S, Ross JS. U.S. Prescribing of On-and-Off-Label Medications for Alcohol Use Disorder in Outpatient Visits: NAMCS 2014 to 2016. Journal Of General Internal Medicine 2021, 37: 495-498. PMID: 33674920, PMCID: PMC8811103, DOI: 10.1007/s11606-021-06668-x.Peer-Reviewed Original Research
2020
Characteristics of Ongoing Clinical Trials for Alcohol Use Disorder Registered on ClinicalTrials.gov
Wallach JD, Krystal JH, Ross JS, O’Malley S. Characteristics of Ongoing Clinical Trials for Alcohol Use Disorder Registered on ClinicalTrials.gov. JAMA Psychiatry 2020, 77: 1081-1084. PMID: 32459295, PMCID: PMC7254444, DOI: 10.1001/jamapsychiatry.2020.1167.Peer-Reviewed Original ResearchPatient and provider-level factors associated with changes in utilization of treatments in response to evidence on ineffectiveness or harm
Smith LB, Desai NR, Dowd B, Everhart A, Herrin J, Higuera L, Jeffery MM, Jena AB, Ross JS, Shah ND, Karaca-Mandic P. Patient and provider-level factors associated with changes in utilization of treatments in response to evidence on ineffectiveness or harm. International Journal Of Health Economics And Management 2020, 20: 299-317. PMID: 32350680, PMCID: PMC7725279, DOI: 10.1007/s10754-020-09282-2.Peer-Reviewed Original ResearchConceptsPermanent atrial fibrillationType 2 diabetesAtrial fibrillationPermanent atrial fibrillation patientsProvider-level factorsAtrial fibrillation patientsEffective new therapiesPrimary care providersUse of medicationsProvider-level characteristicsUtilization of treatmentHigh-quality health careDronedarone useInterrupted time-series regression modelsFibrillation patientsMedication useDiabetes patientsProvider characteristicsCare providersMedicare feeNew therapiesService claimsFemale providersPatientsMedications
2017
Association between FDA black box warnings and Medicare formulary coverage changes.
Dhruva SS, Karaca-Mandic P, Shah ND, Shaw DL, Ross JS. Association between FDA black box warnings and Medicare formulary coverage changes. The American Journal Of Managed Care 2017, 23: e310-e315. PMID: 29087169.Peer-Reviewed Original ResearchConceptsFDA black box warningBlack box warningNew black box warningsBox warningCardiovascular riskDrug alternativesNew safety informationMajority of drugsFormulary changeRetrospective analysisFormulary coverageFormularyDrugsCapsule formulationSubstantial proportionMedicationsDeathRiskSafety informationFDAYears
2014
Decision-making and cancer screening: A qualitative study of older adults with multiple chronic conditions
Gross CP, Fried TR, Tinetti ME, Ross JS, Genao I, Hossain S, Wolf E, Lewis CL. Decision-making and cancer screening: A qualitative study of older adults with multiple chronic conditions. Journal Of Geriatric Oncology 2014, 6: 93-100. PMID: 25544380, DOI: 10.1016/j.jgo.2014.12.001.Peer-Reviewed Original ResearchConceptsCancer screening decisionsCancer screeningChronic conditionsCancer statusEducational promptsOlder personsMultiple chronic conditionsScreening decisionsDirect health benefitsMedical conditionsOverall healthOlder adultsThematic saturationHealth benefitsLife expectancyIndependent readersHealth scenarioMost respondentsScreeningAdultsAgeQualitative studySample sizeStatusMedicationsMarketing to Physicians in a Digital World
Manz C, Ross JS, Grande D. Marketing to Physicians in a Digital World. New England Journal Of Medicine 2014, 371: 1857-1859. PMID: 25390738, DOI: 10.1056/nejmp1408974.Commentaries, Editorials and Letters
2013
Medical school gift restriction policies and physician prescribing of newly marketed psychotropic medications: difference-in-differences analysis
King M, Essick C, Bearman P, Ross JS. Medical school gift restriction policies and physician prescribing of newly marketed psychotropic medications: difference-in-differences analysis. The BMJ 2013, 346: f264. PMID: 23372175, PMCID: PMC3623604, DOI: 10.1136/bmj.f264.Peer-Reviewed Original ResearchMeSH KeywordsAntidepressive AgentsAntipsychotic AgentsCase-Control StudiesCentral Nervous System StimulantsCyclohexanolsDesvenlafaxine SuccinateDextroamphetamineDrug IndustryGift GivingHealth Care SectorHumansInterprofessional RelationsIsoxazolesMarketing of Health ServicesOrganizational PolicyPaliperidone PalmitatePractice Patterns, Physicians'Psychotropic DrugsPyrimidinesSchools, MedicalUnited StatesConceptsPsychotropic medicationsSubsequent prescribing behaviorPhysician prescribingPsychotropic classesOlder antipsychoticsPrescribing behaviorMAIN OUTCOMEMedicationsMedical schoolsPrescribingPhysiciansAntipsychoticsRestriction policiesDesvenlafaxinePaliperidoneStimulantsUS medical schoolsExposureLonger exposureAntidepressantsCohort
2012
State Medicaid Programs Did Not Make Use Of Prior Authorization To Promote Safer Prescribing After Rosiglitazone Warning
Ross JS, Jackevicius C, Krumholz HM, Ridgeway J, Montori VM, Alexander GC, Zerzan J, Fan J, Shah ND. State Medicaid Programs Did Not Make Use Of Prior Authorization To Promote Safer Prescribing After Rosiglitazone Warning. Health Affairs 2012, 31: 188-198. PMID: 22232110, PMCID: PMC3319744, DOI: 10.1377/hlthaff.2011.1068.Peer-Reviewed Original ResearchConceptsState Medicaid programsPreferred drugDrug listPrior authorizationMedicaid programSafety warningsPrior authorization programHigh-cost drugsDiabetes medicationsPrescribing ratesEffective prescribingSafe prescribingMedicaid beneficiariesDiabetes drugsPrescribingState MedicaidHeart attackRosiglitazoneDrug availabilityDrugsAuthorization programPrescriptionMinimal changesMedicationsProviders